These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22683778)

  • 1. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
    Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
    Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
    Balko JM; Schwarz LJ; Bhola NE; Kurupi R; Owens P; Miller TW; Gómez H; Cook RS; Arteaga CL
    Cancer Res; 2013 Oct; 73(20):6346-58. PubMed ID: 23966295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
    Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
    Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.
    Rottenberg S; Jonkers J
    Breast Cancer Res; 2012 Nov; 14(6):324. PubMed ID: 23127286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of Dual-Specific Phosphatase 4 mRNA Expression Before and after Neoadjuvant Chemotherapy in Breast Cancer.
    Prihantono P; Usman AN; Binekada C; Hatta M; Islam AA
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1051-1055. PubMed ID: 31030473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
    Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
    Exp Cell Res; 2013 Dec; 319(20):3140-9. PubMed ID: 24012960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
    Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
    Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
    Mazumdar A; Poage GM; Shepherd J; Tsimelzon A; Hartman ZC; Den Hollander P; Hill J; Zhang Y; Chang J; Hilsenbeck SG; Fuqua S; Kent Osborne C; Mills GB; Brown PH
    Breast Cancer Res Treat; 2016 Aug; 158(3):441-54. PubMed ID: 27393618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox activation of DUSP4 by N-acetylcysteine protects endothelial cells from Cd²⁺-induced apoptosis.
    Barajas-Espinosa A; Basye A; Jesse E; Yan H; Quan D; Chen CA
    Free Radic Biol Med; 2014 Sep; 74():188-199. PubMed ID: 24973647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition.
    Cagnol S; Rivard N
    Oncogene; 2013 Jan; 32(5):564-76. PubMed ID: 22430215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway.
    Al-Mutairi MS; Habashy HO
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DUSP4 is involved in the enhanced proliferation and survival of DUSP4-overexpressing cancer cells.
    Ratsada P; Hijiya N; Hidano S; Tsukamoto Y; Nakada C; Uchida T; Kobayashi T; Moriyama M
    Biochem Biophys Res Commun; 2020 Jul; 528(3):586-593. PubMed ID: 32505357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas.
    Ichimanda M; Hijiya N; Tsukamoto Y; Uchida T; Nakada C; Akagi T; Etoh T; Iha H; Inomata M; Takekawa M; Moriyama M
    Cancer Sci; 2018 Jan; 109(1):250-258. PubMed ID: 29150975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.
    Zhang R; Wang G; Zhang PF; Zhang J; Huang YX; Lu YM; Da W; Sun Q; Zhu JS
    J Cell Mol Med; 2017 Jun; 21(6):1117-1127. PubMed ID: 27957827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
    Gupta A; Towers C; Willenbrock F; Brant R; Hodgson DR; Sharpe A; Smith P; Cutts A; Schuh A; Asher R; Myers K; Love S; Collins L; Wise A; Middleton MR; Macaulay VM
    Br J Cancer; 2020 Feb; 122(4):506-516. PubMed ID: 31839677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Specificity Phosphatase 4 Promotes Malignant Features in Colorectal Cancer Through Cyclic-AMP Response Element Binding Protein/Protein Kinase CAMP-Activated Catalytic Subunit Beta Activation.
    Pei W; Yin W; Yu T; Zhang X; Zhang Q; Yang X; Shi C; Shen W; Liu G
    Dig Dis Sci; 2024 Aug; 69(8):2856-2874. PubMed ID: 38824257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
    Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
    Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
    [No Abstract]   [Full Text] [Related]  

  • 18. The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib.
    Cheng G; Li Y; Liu Z; Song X
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33495832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
    Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
    Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma.
    Schmid CA; Robinson MD; Scheifinger NA; Müller S; Cogliatti S; Tzankov A; Müller A
    J Exp Med; 2015 May; 212(5):775-92. PubMed ID: 25847947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.